{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218240","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2026-05-12T12:08:34+00:00","discovered_at":"2026-05-12T12:10:00.383265+00:00","generated_at":"2026-05-12T12:13:17.200168+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients","bullets":["Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).","Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.","Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.","New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218240","json":"https://secwatch.observer/filing/0001193125-26-218240.json","markdown":"https://secwatch.observer/filing/0001193125-26-218240.md","text":"https://secwatch.observer/filing/0001193125-26-218240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:13:17.200168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"761922fce27b3cdb48b230a71eceb55dc892d511","claim":"Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"Research and Development Expenses : Research and development expenses were $7.6 million for the quarter ended March 31, 2026, compared with $6.0 million for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"761922fce27b3cdb48b230a71eceb55dc892d511","claim":"Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"General and Administrative Expenses : General and administrative expenses were $4.3 million for the quarter ended March 31, 2026, compared with $4.3 million for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}